• Revenues increased by 4% to $36.93m
• Profit after tax decreased by 26% to $10.443m
• Cash reserves increased by 4% to $233m

Clinuvel Pharmaceuticals Ltd has reported its financial results for the half year ended 31 December 2025. The company recorded a 4% increase in revenues to $36.93m, the highest result ever for a December half year. This was driven by continued growth in commercial and Special Access Scheme sales of SCENESSE for the treatment of erythropoietic protoporphyria (EPP), particularly across Europe. Interest income also increased by 14% due to higher average cash reserve balances and favourable term deposit rates. However, total reported revenues decreased by 6% to $40.56m due to a $4.7m movement in unrealised foreign exchange translations at balance date. Expenses increased by 22% to $25.98m as the company accelerated activities across R&D, clinical, commercial, and corporate functions as part of its multi-year growth strategy. This included higher personnel-related costs, materials and related expenses, commercial distribution costs, and finance, corporate and general expenses. Profit after tax decreased by 26% to $10.443m. Cash, cash equivalents and term deposits increased by 4% to $233m, providing a strong financial position to support the company's commercial operations and development programs.

The company did not provide any high-importance, price-sensitive forward-looking financial metrics.